Pharmaceutical Technology

JANUARY 2, 2023

South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.

Licensing 130

Licensing Licensing Production Sales 130

Pharmaceutical Technology

DECEMBER 5, 2022

Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. TherapeuticsMD will also get a 20-year royalty stream linked to Mayne’s net product sales.

Licensing 130

Licensing Licensing Production Marketing 130

Pharmaceutical Technology

MAY 3, 2023

Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.

Licensing 130

Licensing Licensing Development Sales 130

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Denali is also expected to receive potential development and commercial milestone payments upon achieving certain milestones, along with royalties based on the future net sales of the drug.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Pharmaceutical Technology

OCTOBER 4, 2022

Shionogi will waive royalty payments on product sales in all countries under this deal as long as Covid-19 is listed by the World Health Organization as a Public Health Emergency of International Concern. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.

Licensing 147

Licensing Licensing Manufacturing Medicine 147

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 23, 2023

With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.

Pharmacy 188

Pharmacy Sales Licensing Licensing 188

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Pharmaceutical Technology

JANUARY 23, 2023

As per the terms of the agreement, HUTCHMED will receive an upfront payment of $400m on the closing of the deal, along with additional potential payments of up to $730m in regulatory, development and commercial sales milestones and royalties on net sales. The submission is planned to be completed in the first half of this year.

Licensing 130

Licensing Licensing Sales Medicine 130

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. Tiered royalties on net sales are also included in the deal. FAP-2286 is being investigated as a peptide-targeted radionuclide therapy.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.

Protein 130

Protein Licensing Licensing Sales 130

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 16, 2023

At least seven more pharma companies and a federation of pharma manufacturers have approached the Delhi High Court against the Central Government’s order in the beginning of June prohibiting manufacturing, distribution and sale of 14 fixed dose combinations (FDCs) licensed prior to the year 1988.

Pharma Companies 188

Pharma Companies Licensing Licensing Manufacturing 188

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 11, 2023

The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]

Pharma Companies 186

Pharma Companies Licensing Licensing Sales 186

BioPharma Reporter

MAY 6, 2021

The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.

Licensing 94

Licensing Licensing Vaccination Vaccine 94

Bio Pharma Dive

APRIL 13, 2022

Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.

Drug Delivery 141

Drug Delivery Licensing Licensing Sales 141

pharmaphorum

SEPTEMBER 27, 2022

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. The post Lava fires up a $700m cancer licensing deal with Seagen appeared first on.

Licensing 111

Licensing Licensing FDA Approval Clinical Trials 111

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions. mRNA ambitions.

Sales 100

Sales Vaccination Vaccine Drugs 100

Pharmaceutical Technology

APRIL 21, 2023

Astellas will license a suite of single-domain antibody (VHH) libraries from Twist for five years to conduct research and development activities. The company is also expected to receive royalty payments on sales of the product.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

OCTOBER 21, 2022

Roche also holds an option for licensing second arenaviral cancer immunotherapy. Following the marketing of both programmes, Hookipa will also receive tiered royalty payments on the global net product sales. According to the agreement, Roche will make $25m in upfront payment to Hookipa. .

Development 278

Development Production Licensing Licensing 278

Pharma Times

JULY 9, 2021

First ever contraceptive pill to gain a license for over-the-counter sale in the UK

Licensing 123

Licensing Licensing Sales 123

Pharmaceutical Technology

MAY 1, 2023

The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Nicox granted exclusive license to Ocumension to develop and commercialise Zerviate in China and most of the Southeast Asian markets.

Licensing 162

Licensing Licensing Sales Packaging 162

Pharmaceutical Technology

DECEMBER 19, 2022

Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. Initially, the companies signed a research collaboration and licensing agreement in 2016 to develop and assess up to two bispecific NK cell engagers.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

MAY 12, 2023

BlissBio has the potential to earn up to $2bn in commercial milestone payments, as well as royalties on sales if Eisai exercises its option to license the drug. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Clinical Trials 162

Clinical Trials Clinical Trials Licensing Licensing 162

pharmaphorum

FEBRUARY 28, 2024

Viatris licenses two late-stage drugs from Idorsia for heart attack and lupus, both claimed to have blockbuster sales potential, for $350m upfront.

Licensing 115

Licensing Licensing Sales Drugs 115

World of DTC Marketing

FEBRUARY 11, 2022

The corporation is making as much as $1 million in profits every hour from vaccine sales, according to Oxfam, and its executives boast that revenues will expand exponentially in 2022. ( The Atlantic ).

Vaccination 212

Vaccination Vaccine Sales Licensing 212

Pharmaceutical Technology

JULY 4, 2022

Following the option exercise, Vir will receive the option exercise fee, regulatory and commercial milestone payments as well as tiered royalties on net product sales from Brii Bio. A widely neutralising monoclonal antibody (mAb), VIR-3434 (BRII-877) acts on the hepatitis B virus (HBV).

Antibody 279

Antibody Genotype Development Licensing 279

Pharmaceutical Technology

AUGUST 10, 2022

Furthermore, Cerevance will simultaneously out-license a discovery-stage programme to Merck under the partnership. Cerevance will also potentially receive royalty payments on sales of approved products resulting from the partnership.

Licensing 223

Licensing Licensing Sales Development 223

Pharmaceutical Technology

MAY 10, 2023

According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). billion in global sales in 2029, while Truvada estimates amount to $30 million.

Drugs 264

Drugs FDA Approval Containment Licensing 264

Fierce Pharma

FEBRUARY 29, 2024

exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie. As Johnson & Johnson's U.S.

Licensing 93

Licensing Licensing Sales Drugs 93

pharmaphorum

SEPTEMBER 2, 2020

Jounce could also receive up to $685 million in future clinical, regulatory and commercial milestone payments, as well as royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. The post Gilead licenses Jounce immunotherapy for $800m appeared first on.

Licensing 72

Licensing Licensing Antibody Immune Response 72

pharmaphorum

AUGUST 1, 2024

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)

Vaccination 105

Vaccination Vaccine Pharma Companies Licensing 105

Fierce Pharma

JANUARY 11, 2024

With sales declining for aging MS drug Fampyra, Biogen has exercised an option to return licensing rights outside of the U.S. to Acorda Therapeutics.

Licensing 99

Licensing Licensing Drugs Sales 99

pharmaphorum

AUGUST 18, 2021

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. . TALi is also in line for royalties on sales.

Licensing 64

Licensing Licensing Sales FDA Approval 64

Pharmaceutical Technology

JUNE 21, 2023

Already a big player in haemophilia treatments, CSL licensed exclusive global rights to Hemgenix from gene therapy developers uniQure back in 2021. UniQure announced that it had received $100m from this first commercial sale milestone, on top of a $450m upfront payment. Haemophilia B is a rare condition.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. C4T can also earn up to $357m in milestone payments and receive low to mid-double-digit percentage royalties on net sales of the product in greater China.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Pharmaceutical Technology

JANUARY 6, 2023

Dutch biotechnology company Synaffix and Amgen have entered a licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). For four future programmes, Amgen will also have an option for exercising exclusive licenses for research and commercialisation. This is Synaffix’s 12th licensing agreement to date.

Development 130

Development Licensing Licensing Antibody 130

BioPharma Reporter

SEPTEMBER 6, 2022

Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.

Licensing 52

Licensing Licensing Sales Regulation 52